US8754073 — Substituted piperazino-dihydrothienopyrimidines
Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-11-26 · 4y remaining
What this patent protects
This patent protects a class of compounds, specifically piperidinodihydrothienopyrimidines, for use in treating various diseases and complaints.
USPTO Abstract
Piperidinodihydrothienopyrimidines of formula 1 wherein X is SO or SO 2 (preferably SO), and R 1 , R 2 , R 3 , and R 4 may have the meanings given in the disclosure and claims, pharmacologically acceptable salts thereof, and pharmaceutical compositions containing these compounds. These piperidinodihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system, or cancers.
Drugs covered by this patent
- Jascayd (NERANDOMILAST) · Boehringer Ingelheim
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4298 |
— | Jascayd |
U-4298 |
— | Jascayd |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.